These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Tumor-specific immunotherapy: active immunotherapy by augmenting the induction of tumor-specific effector T cells through a T-T cell interaction mechanism]. Kosugi A; Fujiwara H; Hamaoka T Gan To Kagaku Ryoho; 1984 Aug; 11(8):1527-35. PubMed ID: 6236750 [TBL] [Abstract][Full Text] [Related]
8. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model. Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245 [TBL] [Abstract][Full Text] [Related]
9. Active vaccination after allogeneic bone marrow cell transplantation: a new option in the immunotherapy of cancer? Zöller M; Matzku S Arch Immunol Ther Exp (Warsz); 2002; 50(3):197-224. PubMed ID: 12098935 [TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy: a treatment for the masses. Blattman JN; Greenberg PD Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469 [TBL] [Abstract][Full Text] [Related]
11. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity. Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010 [TBL] [Abstract][Full Text] [Related]
12. Antitumor vaccination: where we stand. Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658 [TBL] [Abstract][Full Text] [Related]
13. Current developments in cancer vaccines and cellular immunotherapy. Ribas A; Butterfield LH; Glaspy JA; Economou JS J Clin Oncol; 2003 Jun; 21(12):2415-32. PubMed ID: 12805342 [TBL] [Abstract][Full Text] [Related]
14. [Development in the immunotherapy of malignant melanoma]. Tritsch H Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300 [TBL] [Abstract][Full Text] [Related]
15. [Immunotherapy for cancer--modern immunologic strategies in oncology]. Halama N; Zoernig I; Jäger D Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564 [TBL] [Abstract][Full Text] [Related]
16. Tumor vaccine: current trends in antigen specific immunotherapy. Baral R Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903 [TBL] [Abstract][Full Text] [Related]
17. Immunologic targeting: how to channel a minimal response for maximal outcome. Slovin SF Curr Opin Urol; 2006 May; 16(3):179-85. PubMed ID: 16679856 [TBL] [Abstract][Full Text] [Related]
18. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy. Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648 [TBL] [Abstract][Full Text] [Related]
19. Humoral and cellular immune responses: independent forces or collaborators in the fight against cancer? Reilly RT; Emens LA; Jaffee EM Curr Opin Investig Drugs; 2001 Jan; 2(1):133-5. PubMed ID: 11527005 [TBL] [Abstract][Full Text] [Related]
20. Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects. Minev BR; Guo F; Gueorguieva I; Kaiser HE In Vivo; 2002; 16(6):405-15. PubMed ID: 12494883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]